All sites are expected to participate in the ancillary clinical trials associated with the ALFSG network: 1) the 13C-Methacetin breath test (MBT) trial, evaluating a promising method of determining prognosis for patients with ALI and ALF; For any patient enrolled in the overall ALFSG Registry, the site-PI will also be expected to consider enrollment in each in the MBT trial depending upon specific inclusion and exclusion criteria. The MBT will require separate consent and additional coordinator time for patient management and overall management of the testing process, as well as data collection and transmission to the DCU.
|Effective start/end date||2/19/16 → 8/31/20|
- University of Texas Southwestern Medical Center (GMO160216//5U01DK058369-19)
- National Institute of Diabetes and Digestive and Kidney Diseases (GMO160216//5U01DK058369-19)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.